Trial Profile
Phase III long-term study of KRP-108 -open-label, non-controlled, long-term study of KRP-108 in pediatric bronchial asthma-
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Kyorin Pharmaceutical
- 05 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.
- 03 Jul 2017 New trial record